HDR brachytherapy combined with external beam radiation for localised prostate cancer: Early experience from the Sydney Cancer Centre

Abstract

Our cohort experienced toxicity similar to previously published HDR boost series with very promising early efficacy results.

High-dose-rate brachytherapy boost in prostate cancer: a New Zealand case series

“…We analysed outcomes of the first 137 patients receiving prostate HDRBT as a form of dose escalation from 2006 to 2010. Our BPFS rates are comparable with other larger international centres 15 – 17 . In particular, our high-risk cohort compared favourably with a relatively higher BPFS.…”

Is modern external beam radiotherapy with androgen deprivation therapy still a viable alternative for prostate cancer in an era of robotic surgery and brachytherapy: A comparison of Australian series

“…A total of 791 articles were returned by the Medline search, of which 517 were during or after 2005. There were eight contemporary published Australian studies suitable for comparison, with six reporting high‐dose rate brachytherapy (HDRB) outcomes, one reporting open prostatectomy (OP) outcomes and one reporting robotic‐assisted radical laparoscopic prostatectomy (RALP) outcomes . One low‐dose rate brachytherapy (LDRB) series was also found in the online journal .…”

“…In Australia, most of the recent published series focus on surgical advances (e.g. robotic‐assisted radical prostatectomy or RARP) and brachytherapy . There are few reports evaluating the results of modern EBRT .…”

Brachytherapy in Men with Prostate Cancer: Update on Indications and Outcomes

“…Recentemente, diversi Autori hanno riportato buoni risultati in termini di sopravvivenza globale e cancro-specifica (95-100%) e libera da progressione della malattia (80-90% a 5 anni) con follow-up medio-lunghi (5-10 anni). In letteratura vengono riportati dati riguardanti l'associazione sia della BT LDR che della BT HDR con risultati sostanzialmente sovrapponibili tra di loro in termini di sopravvivenza libera da progressione biochimica e sicuramente sensibilmente migliori nei pazienti a rischio intermedio rispetto a quelli ad alto rischio (79-93% LDR + RT rischio intermedio, 67-86% LDR + RT alto rischio, 83-100% HDR + RT rischio intermedio, 57-90% HDR + RT alto rischio) (68)(69)(70)(71)(72)(73)(74)(75)(76)(77)(78)(79)(80)(81)(82)(83)(84). Uno studio di confronto tra la terapia di combinazione (EBRT + HDR-BT) e la EBRT a intensità modulata in pazienti con malattia a rischio intermedio/alto ha riportato un vantaggio per la prima in termini di sopravvivenza libera da progressione biochimica a 5 anni (98% vs 84% e 93% vs 71% per i rischi intermedio e alto rispettivamente) (68).…”